Sangamo Q1 net loss $31M; cash only into Q3 2026; stock delisted to OTCQB

SANGAMO THERAPEUTICS, INC

2026-Q1 EPS reported -$0.08 revenue$1,442,000

Q1 2026 net loss $31.0M ($0.08/share) vs $30.6M loss in Q1 2025; revenue dropped to $1.4M from $6.4M.
Cash and cash equivalents $27.6M as of March 31 – expects to fund operations only into Q3 2026.
Common stock delisted from Nasdaq, now trading on OTCQB; hearing to appeal delisting scheduled June 9.
Rolling BLA for Fabry gene therapy ST-920 underway; CMC module completion expected summer 2026 subject to funding.
2026 GAAP operating expense guidance $110M-$130M; company warns guidance depends on securing additional funding.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.